A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
OHSU Knight Cancer Institute
Eli Lilly and Company
Pfizer
Albert Einstein College of Medicine
Augusta University
Dana-Farber Cancer Institute
University of Arizona
University of Arizona
Washington University School of Medicine
Eli Lilly and Company
Eli Lilly and Company
SCRI Development Innovations, LLC
Eli Lilly and Company